Juan Fueyo

Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Juan Fueyo is a Professor at The University of Texas MD Anderson Cancer Center, USA. His research focuses on immunotherapy, particularly the use of oncolytic viruses for cancer treatment in pediatric populations. Recent articles authored by him explore topics such as viroimmunotherapy for brain tumors, immune checkpoint enhancement in oncolytic virotherapy, and clinical trials involving the delivery of oncolytic adenoviruses.

Articles (13)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Cor, H.J. Lamers

Assistant professor

Erasmus University Medical Center

NETHERLANDS

View details

Hong Jiang

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

marisol gonzalez-huarriz

Clinica Universidad de Navarra

SPAIN

View details

Candelaria Gomez-Manzano

Professor, tenure

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jiasen He

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Juan Fueyo

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Immunotherapy-related neurotoxicity in the central nervous system of children with cancer

The multilayered control of acetylation during adenovirus-based immunotherapy of cancer

The emerging field of viroimmunotherapy for pediatric brain tumors

Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity

Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies

An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy

Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations

Collaborators (5)

Cor, H.J. Lamers

Hong Jiang

marisol gonzalez-huarriz

Candelaria Gomez-Manzano

Jiasen He

Make your next move.